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Abstract. Traditional animal models have been used to make seminal discoveries in biomedical research including a better
understanding of the biology of the aging process. However, translation of these findings from laboratory to clinical populations
has likely been hindered due to fundamental biological and physiological differences between common laboratory animals
and humans. Non-human primates (NHP) may serve as an effective bridge towards translation, and short-lived NHP like the
common marmoset offer many advantages as models for aging research. Here, we address these advantages and discuss what
is currently understood about the changes in physiology and pathology that occur with age in the marmoset. In addition,
we discuss how aging research might best utilize this model resource, and outline an ongoing study to address whether
pharmaceutical intervention can slow aging in the marmoset. With this manuscript, we clarify how common marmosets
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1. Challenges of translation from laboratory20
animals (mostly rodents) to humans21
Animal models have been a critical resource in22
the quest to evaluate physiological functional decline23
associated with aging and elucidate the cellular path-24
ways and mechanisms associated with longevity. In25
general, these studies have focused most of their26
efforts on delineating the aging process using four27
primary laboratory organisms: yeast (Saccharomyces28
cerevisiae), roundworms (Caenorhabditis elegans),29
fruit flies (Drosophila melanogaster) and rodents30
including mice and rats (Mus musculus and Rat-31
tus norvegicus, respectively) [1]. These species have32
many practical advantages over other animal models33
∗Corresponding author: Corinna N. Ross, PhD. E-mail:
cnross@tamusa.edu and Adam B. Salmon, PhD. E-mail:
salmona@uthscsa.edu.
(including humans) as models of aging including 34
their relatively short lifespan, the ability to breed and 35
maintain large numbers of animals in the laboratory, 36
and the ability to control environmental exposure for 37
each individual (or a population). In addition, over 38
the last few decades it has been shown clearly that 39
the relative ease of manipulating genes of interest; 40
i.e., generating organisms with specific genetic muta- 41
tions to address mechanisms of phenotype including 42
longevity, is a powerful tool for the study of aging. 43
Using these models has been extremely fruitful 44
for geroscience research and has driven discover- 45
ies of conserved biochemical pathways associated 46
with longevity, and allowed the comparative eval- 47
uation of the effect of aging on metabolism and 48
development, mitochondrial stress pathways, adeno- 49
sine monophosphate-activated protein kinase, and 50
insulin-like growth factor [2, 3]. In particular, the 51
widespread use of mice, and in particular genetic 52
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mutant lines of mice, have driven exponential growth53
in our understanding of the particular mechanistic54
pathways on the mammalian aging process [4]. In55
terms of “translational” approaches to addressing56
aging and longevity in humans, mice and rats have57
served a central role in identification and elucida-58
tion of interventional and therapeutic treatments on59
aging and health-span. Most notably, the gold stan-60
dard for extending lifespan in a model organism is61
the use of caloric restriction and indeed the seminal62
studies of caloric restriction have largely been per-63
formed using mice and rats [5–9]. In addition, many64
new drugs of geroscience interest have been tested65
in rodents and continue to reveal details regarding66
aging and disease progression, and have yielded novel67
findings about the anti-aging effect of intervention68
with pharmaceutical and nutraceutical compounds69
[10–17]. In many ways, interventional approaches70
utilizing pharmaceuticals seem to be the most “turn-71
key” for benefiting human health in terms of their72
relative ease of translation for clinical consideration.73
However, there remain many concerns regarding74
using rodents as a model of human model of aging75
(in addition to disease, physiology, pathology, etc.)76
as a foundation for designing treatments and inter-77
ventions to improve human health. Unfortunately,78
a litany of findings in rodent translational research79
have revealed that many of the drugs tested in rodents80
do not translate successfully to humans, either having81
few similar effects or having toxicity in humans [18].82
Further, the development of inbred strains of mice83
has introduced the perpetuation of many traits that84
are a by-product of selection for breeding, rather than85
traits of interest. Many of these traits are undetected86
or unknown and may be detrimental to longevity87
studies or have unknown impact on the research of88
interest [19]. Lastly, there is a distinct dichotomy89
between rodents and humans in terms of the spec-90
trum of diseases that naturally occur with old-age91
or otherwise. Particularly challenging are the wide-92
range of diseases and pathologies that plague aging93
humans that do not naturally exist in rodents (e.g.,94
neurodegenerative diseases including Alzheimer’s95
disease, cardiovascular disease, diabetes, and a host96
of others) due to differences between species in their97
basic physiology, the dramatic differences in their98
maximum ages, diet and environmental conditions99
or other unknown variables. Specifically because100
of such challenges, there has been significant101
investment in drawing from comparative biology to102
identify additional animal models that may serve as103
stronger bridges to clinical translation.
2. How non-human primates are useful 104
(critical) to this process 105
Non-human primate (NHP) models are of particu- 106
lar interest for additional pre-clinical testing towards 107
translation due to their close evolutionary history with 108
humans. Old World monkeys and apes are the closest 109
living relatives to humans and share a closer evo- 110
lutionary history with humans than other mammals, 111
and thus more similar genetic, biochemical, behav- 112
ioral and phenotypic outcomes. Old world monkeys 113
split from the ancestors of the human lineage around 114
25 million years ago, and apes, specifically chim- 115
panzees, split as recently as six million years ago 116
[20, 21]. In the limited studies that have examined 117
the aging characteristics of captive chimpanzees, our 118
closest living relatives, the age-related diseases in this 119
species are described as similar to that of humans 120
including the development of heart disease, cancer, 121
and diabetes with advancing age [22–29]. However, 122
chimpanzees are very long lived, with animals in 123
captivity living up to 60 years, thus making them 124
comparable in difficulty to working with human pop- 125
ulations [21]. Additionally, both wild and captive 126
populations of chimpanzees are now classified by 127
the International Union for Conservation of Nature 128
(IUCN) as endangered animalsand the National Insti- 129
tutes of Health (NIH) have effectively ceased funding 130
for invasive research on chimpanzees. In part for these 131
reasons, research using chimpanzees in the laboratory 132
setting has significantly diminished in many countries 133
including the U.S. 134
Other Old World monkeys, including rhesus 135
macaques, have traditionally been of greater focus 136
for biomedical translational research including aging 137
studies [30–35]. Rhesus macaques have a maxi- 138
mum lifespan of approximately 40 years in captivity 139
and their aging phenotypes have been well charac- 140
terized [36, 37]. In addition, a means to monitor 141
cognitive functional decline in this species has been 142
developed and is hypothesized to model the similar 143
decline in human cognition with age [32]. The rhe- 144
sus macaque has also been used to test whether the 145
benefits of caloric restriction on healthy aging trans- 146
late to NHP species [30]. While there continues to 147
be some discussion on the equivocal nature of caloric 148
restrictions’ effect on NHP lifespan in two ongoing 149
research groups, these studies have largely confirmed 150
that calorie restriction reduces the prevalence of car- 151
diovascular disease, type 2 diabetes, and neoplasias 152
[38–45]. Due in part to the long lifespan of this 153
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to these studies, it is unlikely that such in depth NHP155
lifespan studies will be able to be repeated.156
In an attempt to reduce the heavy commitments157
required for aging NHP studies, several shorter-158
lived NHP species have been suggested for longevity159
research including the bush baby (Galago senegalen-160
sis), the grey mouse lemur (Microcebus murinus),161
and the common marmoset (Callithrix jacchus) [46,162
47]. These species all have relatively shorter lifes-163
pans (for each, the maximum lifespan is ∼15–20164
years) compared to Old World monkeys and apes,165
and they offer a number of advantages due to their166
small size and rapid reproduction [46, 47]. Of note,167
it was recently reported that the lifespan of the grey168
mouse lemur could be extended by calorie restriction169
but that this intervention did not alter cognitive or170
motor function [48]. However, of these species, the171
common marmoset has recently emerged as a model172
for aging related research due to growing investiga-173
tions on the changes in physiology, pathology and174
health that occur in this species [49–54].175
3. Marmosets in aging research176
The common marmoset has many characteristics177
that make it attractive as a non-human primate model178
for aging research. As mentioned above, this species179
has a lifespan that is roughly half that of other180
NHP species commonly used in biomedical research181
(Fig. 1). While still quite long compared to rodents,182
this length of time is certainly more amenable to use183
within the career of a single researcher. Moreover,184
there is fiduciary benefit to the shorter lifespan (i.e.,185
half the amount of time paying per diems as other186
long-lived NHP). Along those lines, per diem costs187
tend to be significantly lower for marmosets than188
for other NHP, due in part to the smaller cage and189
space requirements. Their small size also has ben-190
efits in terms of pharmaceutical interventions (i.e.,191
less drug is required per animal) as well as in terms192
of staff safety. Marmosets are also the fastest repro-193
ducing anthropoid primate giving birth to fraternal194
twins on average twice per year [55]. This fast repro-195
duction allows for relatively rapid growth of colonies196
for use in biomedical research. Further, these charac-197
teristics allowed for the development of an specific198
pathogen free (SPF) barrier maintained colony of199
marmosets for aging research which to date has200
displayed extended lifespan when compared to con-201
ventionally housed marmosets [56]. These features202
Fig. 1. Maximum reported lifespans for four primary primate
species used in aging research.
then support the notion that marmosets offer a unique 203
NHP model with many advantages for studying the 204
physiological changes associated with aging. 205
As part of the development of this species as 206
an aging model, there is a growing understanding 207
of the basic aging phenotypes of aging marmosets. 208
For example, a number of skeletal changes associ- 209
ated with aging have been described in marmosets. 210
Marmosets lack adult growth plates and display sim- 211
ilar human age related structural changes in skeletal 212
bone [57]. When treated with a bisphosphate therapy, 213
trabecular number and volume increased in mar- 214
mosets exhibiting age-related bone loss [57]. Further, 215
marmoset bones undergo degeneration of structure 216
associated with bone aging in such bones as the ver- 217
tebrae [58]. 218
With advancing age, marmosets have been 219
reported to lose weight and show dramatic changes in 220
body composition [54, 59]. These patterns are very 221
similar to the types of changes in body weight and 222
composition that occur in the latter half of normal 223
lifespan in humans [60]. Interestingly, the maximum 224
weight achieved by an individual marmoset is signif- 225
icantly associated with the likelihood of survival in 226
older animals, with animals having a peak mass of 227
less than 400 g having decreased survival after eight 228
years of age [54]. Perhaps related to this, marmosets 229
that exhibit increased rates of stretching behavior 230
have a significantly higher 6-month mortality than 231
animals do not display this behavior [50]. Rather than 232
a beneficial behavior, this type of stretching is hypoth- 233
esized to be a posture adopted due to discomfort in 234
the marmoset. It is an atypical posture in which the 235
marmosets hang for extended periods of time from 236
their forelimbs rather than maintaining a more typical 237
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whether this can be attributed to a specific pathology239
but it would certainly be of further interest to identify240
how marmoset activity and ambulatory behavior are241
impacted by physiological declines associated with242
aging.243
There has also been increasing interest in mar-244
mosets as a model to evaluate a number of age-related245
neurological diseases including Parkinson’s disease,246
Huntington’s disease, Alzheimer’s disease, stroke,247
multiple sclerosis and spinal cord injury. Marmosets248
exhibit decreased adult neurogenesis in the den-249
tate gyrus that is evident before the animals would250
typically be classified as aged [61]. Ultrastructural251
examinations of the frontal cortex and hippocam-252
pus for animals more than 12 years of age found253
widespread accumulation of lipofuscin in the glial254
cells, perivascular macrophages and pericytes [62].255
A recent study described an increase in -synuclein256
aggregations in the olfactory bulb and hippocampus257
of aged marmosets [63].  -amyloid deposition has258
been described in the brain of marmosets over the age259
of seven [64], and this data is often used as a crite-260
rion for defining marmosets as aged when they are261
eight years old. However, Ridley [65] did not detect262
β -amyloid in animals under the age of 10 in their263
colony and very little deposition in older animals.264
Marmoset brains have also been evaluated for the265
presence of amyloid beta markers and tau hyperphos-266
phorylation [66] revealing diffuse amyloid plaques267
throughout the cortex of the aged marmosets, but not268
in the younger age groups. Conformational changes269
in tau were detected in all subjects in this study but270
these changes increased in frequency with aging.271
Dystrophic microglia were also significantly more272
likely to exhibit tau hyperphosphorylation than were273
active microglia in this study. However, the inconsis-274
tency between the presence of neurological markers275
at specific ages in the marmosets suggests that there276
may be environmental differences associated with the277
rate of aging between the colonies that have been278
examined.279
As a potential translational model, there have also280
been numerous attempts to apply standard human281
clinical biomarkers of aging to marmosets. To date the282
only reported change in marmoset blood chemistry283
associated with age has been a significant decrease284
in albumin with advancing age [50]. Serum albu-285
min decreases are of particular interest as they are286
a highly predictive of a risk of death in otherwise287
healthy aging humans [67]. In the largest study to date288
of age-related changes in marmoset blood chemistry,289
a cross-sectional analysis of 60 marmosets ranging in290
age from two to 13 years old identified 2500 metabo- 291
lites [68, 69]. Connectivity between the metabolites 292
was found to decrease with age and the abundance 293
of several of the metabolites significantly declined 294
with age [70]. With age, marmosets tend to dis- 295
play increased mean arterial pressure and diastolic 296
pressure, but no age effect on the systolic pressure 297
[71]. Finally, testosterone has been found to decrease 298
in aging male marmosets, but they remain capable 299
of reproduction, and no known phenotypic changes 300
are associated with the decreased testosterone [55, 301
72–74]. 302
An analysis of the pathologies associated with 303
age in marmosets at the New England National Pri- 304
mate Center and the Southwest National Primate 305
Research Center revealed dramatic shifts in the asso- 306
ciated causes of death as animals aged in the colony 307
[50, 54]. Deaths in young adults under the age of 6 308
years were most likely to be due to injury, inflamma- 309
tory bowel disease (IBD) and infection. Both colonies 310
reported rare occurrences of neoplasia and diabetes. 311
In contrast, for marmosets over the age of 6 years 312
the most likely causes of death were infection and 313
IBD, with increasing rates of pathologies typically 314
thought of as age related pathologies in humans and 315
other model organisms including neoplasia, amyloi- 316
dosis, diabetes, cardiac and renal failure. It must be 317
noted that IBD is not a primary cause of mortality in 318
humans and this reflects one of the challenges in using 319
the marmoset as an aging model. On the other hand, 320
the etiology of IBD in the marmoset has been difficult 321
to ascertain and may be driven in part by suscepti- 322
bility to infection in the community housing setting. 323
Supporting this idea, we recently reported that mar- 324
mosets maintained in SPF conditions showed no 325
deaths associated with inflammatory gastrointestinal 326
or infectious disease unlike marmosets maintained 327
in a standard colony setting [56]. A brief summary 328
and comparison of most likely causes of adult death 329
among mice, marmosets, and humans are provided in 330
Fig. 2. 331
While the extent of physiological and behavioral 332
markers that have been evaluated for changes with 333
aging is ever expanding, many things remain to be 334
examined. For example, a common evaluation to 335
assess frailty or health in geriatric patients is the use 336
of walking speed and grip strength. Translating these 337
relatively simple human assessments to marmosets 338
has proven to be challenging. Other indicators of 339
physiological and social resilience are also still lack- 340
ing and need further refinement and development to 341
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Fig. 2. Common causes of death among laboratory mice, laboratory marmosets, and humans (clipart images from www.istockphotos.com).
cognitive health are not as varied and detailed in the343
marmoset as they are for human evaluations. Many of344
the cognitive tools used to evaluate Old World mon-345
keys or apes are beyond the ability of the marmoset346
to be trained for or to complete, and interpretations347
of results can be controversial. Development of new348
cognitive tests and adaptations of human, monkey and349
mouse assessments are ongoing developments.350
4. Scientific approaches to study aging in351
marmosets352
It is now clear that longevity can be altered using353
three primary means in traditional laboratory ani-354
mals: genes, diet, and pharmaceutical interventions355
[13, 75, 76]. These interventional methods are invalu-356
able tools for studying the basic biology of aging and357
there is growing evidence that they can be translated358
to marmoset studies with some considerations.359
While genetic modifications have been valuable360
tools in invertebrate and mouse models of aging, one361
of the biggest disadvantages historically for NHP362
biomedical studies has been the inability to produce363
genetically modified individuals to examine targeted364
areas of interest in ways that are either relatively365
cheap or easy (or hopefully both). There are a few366
reports of transgenic Old World monkeys that exist367
but the production of a single living offspring in these 368
species is generally extraordinarily costly both finan- 369
cially and in terms of time commitment [77, 78]. 370
Moreover, in terms of aging studies the phenotypic 371
symptoms of the gene of interest may not appear 372
until mid- to old-age which could be on the orders 373
of decades. However, transgenic marmosets have 374
existed for nearly a decade with the production of 375
the lentiviral-induced GFP transgenic marmosets first 376
reported in 2009 [79]. In this mutant monkey, the GFP 377
transgene was distributed throughout the somatic 378
cells in addition to a successful germ-line transmis- 379
sion that was verified within 2 years of the birth of the 380
initial infants. Since this first report, a number of facil- 381
ities have produced transgenic lines of marmosets 382
using lentiviral transduction, CRISPR/Cas and Tet- 383
on systems. A process that has a great deal of potential 384
for the production of transgenic marmosets is somatic 385
cell nuclear transfer (SCNT) because it may decrease 386
the likelihood of producing mosaic individuals, but 387
to date these attempts have not been successful [80]. 388
Regarding aging research, many of the transgenic 389
lines proposed and developed using marmosets have 390
focused on neurologic disease and modeling of neu- 391
rodegenerative disorders such as Alzheimer’s and 392
Parkinson’s. Lentiviral transgenic induction of Tet-on 393
human ataxin 3 genes has produced young mar- 394
mosets with neurodegenerative disease phenotype 395
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induction of intracellular calcium indicators have397
been developed in order to greatly advance the tech-398
nology and imaging possibilities [83]. While the399
developing transgenic marmoset models is still cer-400
tainly much more expensive and time consuming than401
developing similar rodent models, the ability to exam-402
ine neurodegenerative disorders and cognitive deficit403
in a NHP will greatly advance our understanding of404
these processes in human aging. Further refinement of405
transgenic marmoset generation will also help expand406
the scientific focus of such models to other areas of407
aging research.408
As mentioned above, calorie restriction has been409
one of most important tools used in aging research410
to understand the basic mechanisms of animal411
aging. Dietary interventions, including both dietary412
restriction and over-nutrition, have been adapted to413
marmoset studies to test the physiological outcomes414
of such interventions [84, 85]. However, these effects415
have not been evaluated in association with aging416
or age- related disease to date. Dietary restriction417
in marmosets has been limited to evaluations of the418
timing of caloric restriction during pregnancy and lac-419
tation to infant outcome [84]. While it is possible to420
restrict marmosets calorically, for some short studies421
such as measuring food intake or evaluation of daily422
food patterning, it is extremely challenging to use423
this intervention under normal housing conditions for424
this animal; i.e., social housing. Marmosets are one of425
the few primates that has been found to actively share426
food with other family members and with infants [86].427
This particular trait of marmosets makes it difficult to428
account for food taken from a hopper by an individ-429
ual animal because even though they remove it from430
a dish, they are not necessarily eating the food by431
themselves. Single housing animals, as would typ-432
ically be done in rodent calorie restriction, is not433
preferred in marmosets due to the social habits (and434
requirements) of this species. One potential approach435
to food restriction might be separating the individual436
of interest during feeding and then removing all food437
from the family housing prior to returning the animal.438
However, this technique is extremely labor intensive439
and it is likely that the entire group’s feeding patterns440
would be shifted in ways that would be challenging441
to document. Another possible approach would be442
to use time-restricted feeding or intermittent fasting,443
though the status of these approaches in comparison444
to “traditional” calorie restriction is still equivocal.445
Thus, there is still opportunity to develop appropri-446
ate caloric restriction paradigms in the marmoset for447
future testing.448
Pharmaceutical interventions are by far the most 449
easily translated to marmoset studies of aging and 450
age-related disease. The marmoset is already a valu- 451
able NHP model for evaluating preclinical drug 452
pharmacokinetics, teratology and toxicity in part due 453
to its small size and thus need for smaller doses 454
of drugs compared to other NHP [87–89]. Their 455
metabolic profile and primate physiology allows 456
drugs to be tested in the same delivery modality 457
as will be used in human dosing, making transla- 458
tion to clinical trials smoother. Marmosets have been 459
key to the development of drugs for use in neu- 460
roscience, immunology and infectious disease [89]. 461
Drug development and testing for multiple sclero- 462
sis, Parkinson’s, stroke, spinal injury, amyloidosis, 463
hepatitis, encephalitis, viral hemorrhagic fevers and 464
bone disease have all relied on marmosets [89]. Thus, 465
an easy case can be made for using this particular 466
approach as the “low-hanging fruit” for refinement 467
of the marmoset as a valuable NHP for studying the 468
basic biology of aging. In this regard, we have put 469
together an aging cohort of marmosets to test the very 470
idea of whether drug intervention can delay the aging 471
process in this NHP. 472
5. Designing a study to address whether 473
rapamycin slows aging in marmosets 474
The work of the Interventions Testing Program 475
and others has identified rapamycin as one of the 476
most consistent (so far) pharmaceutical interventions 477
capable of extending lifespan and improving health 478
in mice [13–15, 17, 90]. Rapamycin is an inhibitor of 479
mTOR (mechanistic target of rapamycin) signaling 480
and this compound, along with some of its analogues, 481
have been shown to delay (if not rejuvenate) the 482
physiological dysfunction and pathologies associated 483
with aging across multiple organs in the aging mouse 484
[90–96]. Collectively, these outcomes have provided 485
the first proof of principle that longevity in mammals 486
can be extended, if not slowed outright, by admin- 487
istration of a pharmaceutical agent. As described 488
above, there are significant challenges in applying the 489
results of intervention testing in rodents towards the 490
benefit of human health. There is some evidence that 491
rapamycin or its orthologs might provide some bene- 492
fit to generally healthy older human populations with 493
limited side-effects [97, 98]. While clinical based trial 494
may reveal additional benefit, they are unlikely in 495
the near future to be capable of determining whether 496
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among humans directly. As discussed here, there498
then is potentially tremendous benefit in addressing499
whether interventions that extend longevity in mice,500
such as rapamycin, similarly extend lifespan in a NHP501
species.502
To this end, we have enrolled a cohort of middle-503
aged marmosets into a long-term study to test the504
effect of rapamycin on longevity and healthy aging in505
this species. During the development of this project,506
we previously characterized the pharmacokinetics of507
daily oral treatment with rapamycin encapsulated508
in a slow-release enteric coating (as used in the509
Intervention Testing Program’s mouse studies). We510
reported that marmosets treated with an oral dose of511
1.0 mg/kg body weight/day rapamycin showed cir-512
culating trough rapamycin concentrations similar to513
those reported in mouse lifespan studies as well as514
similar to the reported therapeutic ranges for humans515
given rapamycin as chemotherapy [99]. Moreover, we516
showedthisdoseof rapamycinwassufficient to inhibit517
mTOR signaling in vivo both in the short (weeks) and518
long (14 months) term. In this pilot study, we also519
reported little to no signs of intolerability among ani-520
mals treated with rapamycin (total 7 animals of mixed521
sexes) and no additional veterinary interventions were522
required of animals who had taken daily treatment523
with this drug for approximately 14 months.524
Our results from this pilot study in large part525
confirmed that we could deliver rapamycin to mar-526
mosets in such a way to at least achieve similar527
blood concentrations (and in vivo mTOR inhibition)528
similar to that reported in mouse longevity studies529
using this drug. While this suggests the basic bio-530
chemical properties of this drug intervention can be531
translated between these species, other results from532
our pilot study support the notion that physiolog-533
ical outcomes of such an intervention may differ534
between species. For example, one of the relatively535
consistent ancillary effects of rapamycin treatment in536
mice has been development of glucose intolerance,537
likely due to an inhibitory effect of rapamycin on538
mTORC2 signaling in the liver [15, 100–102]. How-539
ever, in marmosets treated with rapamycin we found540
no evidence of glucose intolerance measured by oral541
glucose tolerance tests or indices of insulin resis-542
tance [103]. It is unclear exactly why we found these543
discrepancies between species, though one possibil-544
ity might be basic anatomical differences between545
mice and NHP. For example, the liver, which has546
been reported to be at least partially responsible for547
rapamycin-mediated glucose intolerance, makes up548
a greater contribution of the total mass of mice in549
comparison to marmosets. In this regard, marmoset 550
relative liver mass is much more similar to humans 551
than to mice. While this provides no assurance that 552
results from marmosets will directly translate to 553
humans, it does hint at the potential value of utilizing 554
a model species with basic biological characteristics 555
similar to humans in biomedical research. 556
In a similar vein, there has been speculation that 557
at least part of the beneficial effects of rapamycin 558
on longevity are mediated through mTOR’s effects 559
on protein homeostasis (or proteostasis). While the 560
relationships between mTOR and autophagy and 561
mTOR and protein translation are well-understood, 562
there is also growing evidence that mTOR may reg- 563
ulate proteostasis through other pathways such as 564
ubiquitin-proteosome and protein chaperone acti- 565
vation. Indeed, previous reports have suggested 566
that chronic rapamycin treatment can stimulate 567
autophagy, induce proteosome activity and increase 568
expression of protein chaperones [104–107]. In mar- 569
mosets treated with rapamycin, we found evidence 570
for mild stimulation of autophagy in some, though 571
not all, tissues compared to control animals though 572
little to no evidence that other protein degradation 573
pathways, including proteasome and protein chaper- 574
ones, were affected [108]. These data then suggest 575
that if rapamycin has an effect on healthy aging in 576
the marmoset, at least some of this effect might be 577
contributed to activation of autophagy and provides 578
a mechanistic target of action for further study. 579
The goal of our ongoing marmoset study is to 580
directly address the question of whether interven- 581
tion with rapamycin will benefit longevity or healthy 582
aging in this species. As mentioned above, we have 583
recruited and enrolled a cohort of middle-aged mar- 584
mosets into a long-term study to test this question. We 585
have designed this experiment starting with older ani- 586
mals (approximately 5–7 years of age in this species) 587
for three main reasons. 1) This provides a reasonable 588
chance to see effects on longevity in this species over 589
the next 5–10 years. 2) This is similar to the original 590
Interventions Testing Program report on rapamycin 591
which started in middle-aged mice and showed a ben- 592
eficial effect of this drug on longevity [13]. 3) It is 593
reasonable to assume that translation of aging inter- 594
ventions in humans might target those individuals that 595
have reached a period considered later in life [97]. 596
Our cohort is of mixed sex with roughly equivalent 597
numbers of male and female animals. We are treat- 598
ing half of the cohort with rapamycin administered 599
daily at dose of 1 mg/kg body weight which we have 600
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lifespan [99], the other half of this cohort is control602
(i.e., treated daily with the agent used to encapsulate603
rapamycin only). We are tracking physiological and604
behavioral phenotypes as well as health outcomes and605
longevity over the next several years.606
While our primary goal is to assess effects of607
this intervention on longevity in the marmoset, we608
also have the opportunity to examine the effects of609
rapamycin on “healthy aging” or the progression of610
age-related physiological decline. In mice, rapamycin611
has been suggested to delay this progression (or612
even reverse age-related loss) across several organ613
systems with cardiac [91, 93], hematopoietic stem614
cells [96], the immune system [94], and periodontal615
bone [109] benefits among the many reported pos-616
itive outcomes. In our cohort of aging marmosets,617
we are testing the effect of both advancing age and618
rapamycin intervention across multiple minimally-619
invasive assessments of animal health, frailty and620
resilience. For example, changes in blood chemistry,621
complete blood counts, blood lipids, etc. are being622
tested through regular blood draws similar to what623
would be performed during routine physical assess-624
ments in a clinical setting. In addition, we have625
defined scheduled tests of glucose metabolism, car-626
diovascular function, musculoskeletal function and627
inflammatory processes outlined for repeated test-628
ing throughout the remaining lifetime of this cohort.629
These repeated longitudinal tests also give us an630
opportunity to address long-term administration of631
rapamycin to a relatively healthy population has sim-632
ilar potential for side-effects as in clinical use to treat633
specific disease conditions. For example, the most634
commonly cited potential side effects of this drug are635
metabolic dysfunction (including new-onset type 2636
diabetes and dyslipidemia) and immunological sup-637
pression. As mentioned above, we have found so638
far no evidence to suggest rapamycin is impairing639
glucose metabolism at least through approximately640
1 year of treatment and no evidence for dyslipi-641
demia [51]. We continue to monitor these outcomes642
in our long-term treatment cohort. While our design643
does not allow us to directly test changes in immune644
response with age and rapamycin in the marmoset,645
we do monitor changes in blood cell count (includ-646
ing subsets of leukocytes) during our semi-annual647
health checkups. Again, to date we have found little648
evidence that chronic rapamycin significantly alters649
these parameters. Functional tests of immune cell650
function in vivo would at least tangentially address651
whether rapamycin inherently alters the ability of the652
immune cells to address challenge.653
At death, animals will undergo full pathological 654
assessment as well as to tissue collection to assess 655
the effect of chronic intervention with rapamycin 656
on multiple markers that represent the “pillars of 657
aging” [110]. Thus, over the course of this study we 658
should develop a complete picture of not only the 659
broad effects of aging on the common marmoset but 660
also whether pharmaceutical interventions known to 661
extend lifespan in mice have similar effects in a NHP 662
species. 663
6. Conclusions 664
Marmosets offer a unique non-human primate 665
model in which to evaluate both cross-sectional and 666
longitudinal effects of aging on measures of longevity 667
and healthspan. While areas of interest remain for 668
which there are currently no assessment tools for use 669
in the marmoset, recent developments have rapidly 670
expanded tools that are available. Marmosets have 671
significant advantages including relatively short life 672
span and ease of handling that make them ideal for 673
this type of work. We look forward to the continued 674
expansion of tools and knowledge that are becom- 675
ing available for the marmosets as models for aging 676
research. 677
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